Physician profile
Jesse Lyons
NPI 1437716529
$3,929.51
in general payments reported to CMS, 2019-2025
37 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.66 · 2022: $30.61 · 2023: $498 · 2024: $1,842 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,787.24 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.11 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $521.85 | 2023-2025 | |
| Pfizer INC. | $467.76 | 2023-2025 | |
| Novo Nordisk INC | $441.47 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $202.21 | 2023-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $175.13 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $146.57 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $132.10 | 2023-2025 | Arexvy, Shingrix |
| Amgen INC. | $110.49 | 2023-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $103.43 | 2024-2025 | Rexulti |
| Lundbeck LLC | $86.43 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $70.33 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $68.74 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $65.39 | 2023-2025 | Austedo Xr, Ajovy |
| Hologic Sales and Service, LLC | $59.95 | 2024-2025 | Aptima |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.